Annexon, Inc. (ANNX) Stock Score, Valuation & Financial Research

Annexon, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ANNX

Annexon, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 4.03. These figures are a research snapshot, not a buy or sell recommendation.

What Annexon, Inc. does

Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Annexon is a clinical-stage biopharmaceutical company that does not currently have any products approved for commercial sale. Its business model focuses on the research and development of targeted immunotherapies to treat neuroinflammatory diseases, and it currently relies on financing activities to fund its operations until it can achieve regulatory approval and commercialize its product candidates.

Products and services

  • The company is developing a pipeline of complement-mediated therapies, including tanruprubart for Guillain-Barré Syndrome, vonaprument for geographic atrophy, and ANX1502 for autoimmune conditions.

Customer types

Governmental authorities; Health insurers.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party suppliers to manufacture its product candidates and intends to rely on third parties for commercial supplies. Source

Business strengths to evaluate

  • Clinical-stage platform of targeted immunotherapies Source

Business risks and research considerations

  • Limited operating history and no products approved for commercial sale Source
  • Requirement for substantial additional financing Source
  • Reliance on third-party suppliers for manufacturing Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ANNX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 4.03
Market capitalization:
660.29M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -202.67M
Free cash flow:
USD -186.49M
Cash:
USD 199.27M
Total debt:
USD 24.65M
EPS:
USD -1.16

What stands out

  • Free cash flow is USD -186.49M, negative for the stored period.
  • The balance sheet shows USD 199.27M of cash versus USD 24.65M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 174.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ANNX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ANNX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is ANNX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for ANNX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of ANNX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ANNX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.